# fibromyalgia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/fibromyalgia

> 4 upcoming FDA catalysts in fibromyalgia: axs-14 (esreboxetine, AXSM) on March 2028 (primary completion); axs-14 (esreboxetine, AXSM) on Mar to Jun 2028 (topline data readout); axs-14 (esreboxetine, AXSM) on May 2028 (primary completion); axs-14 (esreboxetine, AXSM) on May to Aug 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2026 | [Esreboxetine trial start](https://sec-api.dev/pdufa/esreboxetine) | AXSM | fibromyalgia | completed | "Fibromyalgia: In January 2026, Axsome initiated the FORWARD study, a Phase 3, double-blind, placebo-controlled, randomized withdrawal trial evaluating the efficacy and safety of AXS-14 for the management of fibromyalgia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm)) |
| March 2028 | [Axs-14 (esreboxetine) primary completion](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07398417 (Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07398417)) |
| Mar to Jun 2028 | [Axs-14 (esreboxetine) topline data readout](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07398417 (Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07398417)) |
| May 2028 | [Axs-14 (esreboxetine) primary completion](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07637162 (Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07637162)) |
| May to Aug 2028 | [Axs-14 (esreboxetine) topline data readout](https://sec-api.dev/pdufa/axs-14-esreboxetine) | AXSM | Fibromyalgia | scheduled | "NCT07637162 (Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07637162)) |

## Drugs

- [Esreboxetine](https://sec-api.dev/pdufa/esreboxetine) (AXSM)
- [Axs-14 (esreboxetine)](https://sec-api.dev/pdufa/axs-14-esreboxetine) (AXSM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/fibromyalgia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "fibromyalgia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/fibromyalgia

```bibtex
@misc{secapidev_indications_fibromyalgia_20261116,
  title        = {fibromyalgia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/fibromyalgia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_fibromyalgia_20261116","title":"fibromyalgia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/fibromyalgia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
